NCT00557739

Study of CRx-191 to Assess Activity in Plaque Psoriasis

A Single-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Activity of CRx-191 in Reducing the Psoriatic Infiltrate Band Thickness in Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Zalicus · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis. This clinical trial will assess the effectiveness of CRx-191 in reducing the psoriatic infiltrate band thickness as measured by transdermal ultrasound. All subjects will receive all treatments in separate test fields, with intra-individual comparison of the treatments.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	mometasone furoate	Topical 0.1% mometasone furoate
DRUG	nortriptyline HCl	Topical 0.05% or 0.1% nortriptyline HCl
DRUG	Vehicle (placebo)	Topical placebo

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2007-11-14
• Last updated: 2008-09-25

Locations

1 site across 1 country: Germany